Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

IgA vasculitis

Rheumatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Bowel, renal or systemic IgA-vasculitis complication

Severe abdominal pain, bleeding, intussusception, perforation, rapidly progressive glomerulonephritis, pulmonary haemorrhage or a septic purpuric illness requires immediate hospital care.

Action: Stabilise circulation, obtain blood, urine, renal and abdominal assessment, involve surgery or nephrology, biopsy renal or skin tissue when it changes treatment, and do not assume every purpura-plus-abdominal-pain presentation is benign IgA disease.

Synopsis

Recognise IgA vasculitis from palpable purpura with joint, gastrointestinal and renal involvement, exclude sepsis and other small-vessel disease, detect adult nephritis and bowel emergencies, and organise supportive, organ-specific and long-term renal care.

  • IgA vasculitis classically combines non-thrombocytopenic palpable purpura, usually on dependent legs or buttocks, with arthralgia or arthritis, abdominal pain and renal abnormality.
  • Check observations, full blood count and platelets, coagulation, creatinine, electrolytes, albumin, CRP, urinalysis, microscopy, ACR or PCR and blood pressure at presentation.
  • A normal platelet count helps distinguish vasculitic purpura from thrombocytopenic bleeding but does not exclude meningococcal sepsis or DIC early.
  • Skin biopsy of a fresh lesion shows leukocytoclastic vasculitis; direct immunofluorescence for IgA supports diagnosis when the phenotype is atypical.
  • Severe abdominal pain requires ultrasound or CT and surgical review for intussusception, ischaemia, bleeding and perforation before symptoms are attributed to uncomplicated bowel oedema.
  • Kidney biopsy is indicated for rapidly declining function, substantial persistent proteinuria, nephrotic or nephritic syndrome and other high-risk adult disease because histology changes treatment and prognosis.
  • Mild skin and joint disease is managed with hydration, activity adjustment and cautious analgesia; avoid NSAIDs when renal disease, GI bleeding or dehydration is present.
  • Glucocorticoid can shorten severe joint or abdominal symptoms after surgical and infectious causes are excluded but should not be given solely to prevent future nephritis.
  • Manage established IgA-vasculitis nephritis with pressure and proteinuria reduction, usually ACE inhibitor or ARB when appropriate, and nephrology-directed immunosuppression only for selected active severe disease.
  • Continue urine, protein, blood pressure and eGFR monitoring for at least six months and longer in adults or after any nephritis because renal disease can appear after the rash fades.

Key red flags

Non-blanching rash with hypotension, fever, neck stiffness or rapid progression requires immediate meningococcal and sepsis treatment before vasculitis classification.

Severe colicky abdominal pain, guarding, bilious vomiting, GI bleeding or a palpable mass suggests intussusception, ischaemia or perforation.

Rising creatinine, oliguria, hypertension, nephrotic proteinuria or red-cell casts requires urgent nephrology and possible kidney biopsy.

Scrotal pain requires torsion assessment; oedema and haematuria do not make an acute scrotum automatically vasculitic.

Adult-onset disease has greater CKD risk and needs longer urine, protein, pressure and eGFR follow-up than a transient rash suggests.

Gastrointestinal vasculitis

Colicky pain, vomiting, occult or overt bleeding and bowel-wall oedema can precede purpura and may progress to intussusception.

Renal involvement

Microscopic blood, protein, hypertension, oedema or creatinine change may emerge days to weeks after other symptoms.

Septic purpura mimic

Toxic physiology, fever and rapidly spreading petechiae or ecchymoses require immediate sepsis treatment regardless of a possible vasculitis history.

Investigation priorities

01
FBC, platelets, coagulation and blood filmFirst step

Distinguish non-thrombocytopenic vasculitis from platelet, DIC and microangiopathic bleeding disorders.

Management branches

First-line assessmentConfirm purpura and screen every organ

Palpable non-blanching rash occurs with joint, abdominal or urinary symptoms.

  1. Assess sepsis physiology first, then map rash, joints, abdomen, oedema, scrotum, pressure and urine and review infection and medicines.
  2. Obtain blood count, platelets, coagulation, renal, albumin, inflammatory markers, microscopy and quantitative protein.
  3. Use fresh skin biopsy when atypical and establish a written renal-monitoring schedule even if initial urine is normal.

Key medicines

ParacetamolUse 500 mg–1 g orally up to four times daily when required, at least four hours apart, maximum 4 g in 24 hours, reducing the maximum for low body weight, liver risk or frailty.Count all combination products and avoid overdose; review liver disease, alcohol, malnutrition and body weight. Analgesia must not delay assessment of peritonism or renal deterioration.
Prednisolone for severe abdominal or joint diseaseAfter surgical and infectious emergencies are excluded, specialists may use 1 mg/kg orally once daily, commonly up to 60 mg/day, for one to two weeks followed by a taper based on response.Monitor infection, GI bleeding, glucose, pressure, mood and bone and reassess pain that fails to improve. Do not allow symptom suppression to obscure intussusception or perforation.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • KDIGO IgA nephropathy and IgA vasculitis guidelineRenal biopsy, proteinuria, supportive care and severe nephritis guidance.
  • NHS IgA vasculitis informationUK recognition, complications and follow-up advice.
  • NICE NG203 chronic kidney diseaseProteinuria, ACE inhibition and CKD follow-up.
  • UK Kidney Association IgA vasculitis complications guidelineBiopsy, nephritis, gastrointestinal, intussusception and paediatric complication pathways.
  • Ramipril UK product informationDose, renal, potassium and pregnancy safety.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom